On April 18, 2026, President Donald Trump signed a landmark executive order in the Oval Office designed to dramatically accelerate the research and regulatory review of psychedelic drugs, most notably the controversial compound ibogaine.
Hims & Hers Health’s attempt to launch a low-cost oral weight-loss pill has drawn swift regulatory and legal pushback, threatening the telehealth company’s next major growth strategy and intensifying scrutiny of drug compounders.
19 Apr 2026-16:36
19 Feb 2026-15:30
